BeyondSpring Inc., a clinical-stage global biopharmaceutical company, has released its unaudited financial results for the first quarter ended March 31, 2025. The company reported a net loss from continuing operations of $2.584 million, an increase of 24% compared to the net loss of $2.080 million in the same quarter of 2024. Research and development expenses from continuing operations rose by 21%, amounting to $874,000, up from $721,000 in the prior year. General and administrative expenses also saw a significant increase of 30%, reaching $1.736 million compared to $1.334 million in the same period last year. BeyondSpring provided a corporate update, highlighting advancements in its key programs. Plinabulin has been administered to over 700 patients, demonstrating a favorable safety profile and potential efficacy in patients progressing on PD-1/L1 inhibitors, particularly in metastatic NSCLC and Hodgkin lymphoma. Moreover, SEED Therapeutics, partially owned by BeyondSpring, reported promising results for its RBM39 molecular-glue degrader, achieving durable tumor regression in Ewing sarcoma models. The company plans to pursue additional indications in collaboration with leading cancer research centers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.